Elaine Ku1,2, Rebecca Scherzer3, Michelle C Odden4, Michael Shlipak3, Carole L White5,6, Thalia S Field7, Oscar Benavente5,7, Pablo E Pergola8, Carmen A Peralta1,3. 1. a Division of Nephrology, Department of Medicine , University of California , San Francisco , CA USA. 2. b Division of Pediatric Nephrology, Department of Pediatrics , University of California , San Francisco , CA , USA. 3. c Division of General Internal Medicine, Departments of Medicine, Epidemiology, and Biostatistics , San Francisco Veterans Affair Medical Center, University of California , San Francisco , CA , USA. 4. d College of Public Health and Human Sciences , Oregon State University , Corvallis , OR , USA. 5. e SPS3 Coordinating Center , University of British Columbia , Vancouver , BC , Canada. 6. f School of Nursing , University of Texas Health Sciences Center at San Antonio , San Antonio , TX , USA. 7. g Division of Neurology, Department of Medicine , Brain Research Center, University of British Columbia , Vancouver , Canada. 8. h University of Texas Health Sciences Center at San Antonio , San Antonio , TX , USA.
Abstract
PURPOSE: We applied cluster analysis to identify discrete patterns of concomitant responses of systolic (SBP), diastolic (DBP) and pulse pressure (PP) during intensive BP lowering; and to evaluate their clinical relevance and association with risk of mortality, major vascular events (MVEs), and stroke. MATERIAL AND METHODS: We used an unsupervised cluster procedure to identify distinct patterns of BP change during the first 9 months of anti-hypertensive therapy intensification among 1,331 participants in the Secondary Prevention of Small Subcortical Strokes Trial who were previously randomized to lower BP target (SBP < 130 mm Hg) after lacunar stroke. RESULTS: The cluster procedure partitioned participants into three groups in the lower SBP target arm, persons with: 1) mildly elevated baseline SBP and minimal visit-to-visit BP variability (mild reducers); 2) moderately elevated baseline SBP and moderate visit-to-visit BP variability (moderate reducers); and 3) very elevated baseline SBP with very large visit-to-visit BP variability during intensification (large reducers). In the lower SBP target group, moderate reducers had a higher risk of death (adjusted HR 1.6 [95% CI 1.0-2.7]), MVE (adjusted HR 2.1 [95% CI 1.4-3.2]), and stroke (adjusted HR 2.6[95% CI 1.7-4.1]) compared to mild reducers. Large reducers had the highest risk of death (adjusted HR 2.3 [95% CI 1.2-4.4]), but risk of MVE (HR = 1.7 [95%CI 0.9-3.1]) and stroke (HR = 1.6 [95%CI: 0.8-3.5]) were not statistically significantly different compared to mild reducers. CONCLUSIONS: Among persons with prior lacunar stroke, baseline BP levels, and BP variability in the setting of intensive BP lowering can identify discrete groups of persons at higher risk of adverse outcomes.
RCT Entities:
PURPOSE: We applied cluster analysis to identify discrete patterns of concomitant responses of systolic (SBP), diastolic (DBP) and pulse pressure (PP) during intensive BP lowering; and to evaluate their clinical relevance and association with risk of mortality, major vascular events (MVEs), and stroke. MATERIAL AND METHODS: We used an unsupervised cluster procedure to identify distinct patterns of BP change during the first 9 months of anti-hypertensive therapy intensification among 1,331 participants in the Secondary Prevention of Small Subcortical Strokes Trial who were previously randomized to lower BP target (SBP < 130 mm Hg) after lacunar stroke. RESULTS: The cluster procedure partitioned participants into three groups in the lower SBP target arm, persons with: 1) mildly elevated baseline SBP and minimal visit-to-visit BP variability (mild reducers); 2) moderately elevated baseline SBP and moderate visit-to-visit BP variability (moderate reducers); and 3) very elevated baseline SBP with very large visit-to-visit BP variability during intensification (large reducers). In the lower SBP target group, moderate reducers had a higher risk of death (adjusted HR 1.6 [95% CI 1.0-2.7]), MVE (adjusted HR 2.1 [95% CI 1.4-3.2]), and stroke (adjusted HR 2.6[95% CI 1.7-4.1]) compared to mild reducers. Large reducers had the highest risk of death (adjusted HR 2.3 [95% CI 1.2-4.4]), but risk of MVE (HR = 1.7 [95%CI 0.9-3.1]) and stroke (HR = 1.6 [95%CI: 0.8-3.5]) were not statistically significantly different compared to mild reducers. CONCLUSIONS: Among persons with prior lacunar stroke, baseline BP levels, and BP variability in the setting of intensive BP lowering can identify discrete groups of persons at higher risk of adverse outcomes.
Authors: Oscar R Benavente; Carole L White; Lesly Pearce; Pablo Pergola; Ana Roldan; Marie-France Benavente; Christopher Coffey; Leslie A McClure; Jeff M Szychowski; Robin Conwit; Patricia A Heberling; George Howard; Carlos Bazan; Gabriela Vidal-Pergola; Robert Talbert; Robert G Hart Journal: Int J Stroke Date: 2011-01-26 Impact factor: 5.266
Authors: Pablo E Pergola; Carole L White; Jeff M Szychowski; Robert Talbert; Oscar Del Brutto; Mar Castellanos; John W Graves; Gonzalo Matamala; Edwin Javier Pretell; Jerry Yee; Rosario Rebello; Yu Zhang; Oscar R Benavente Journal: Am J Hypertens Date: 2014-03-07 Impact factor: 2.689
Authors: Ji-Guang Wang; Jan A Staessen; Stanley S Franklin; Robert Fagard; François Gueyffier Journal: Hypertension Date: 2005-04-18 Impact factor: 10.190
Authors: Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Neil R Poulter; Peter S Sever Journal: Lancet Neurol Date: 2010-03-11 Impact factor: 44.182
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Krishna K Patel; Suzanne V Arnold; Paul S Chan; Yuanyuan Tang; Yashashwi Pokharel; Philip G Jones; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2017-04
Authors: Roberto Pastor-Barriuso; José R Banegas; Javier Damián; Lawrence J Appel; Eliseo Guallar Journal: Ann Intern Med Date: 2003-11-04 Impact factor: 25.391
Authors: Paul Muntner; Jeff Whittle; Amy I Lynch; Lisandro D Colantonio; Lara M Simpson; Paula T Einhorn; Emily B Levitan; Paul K Whelton; William C Cushman; Gail T Louis; Barry R Davis; Suzanne Oparil Journal: Ann Intern Med Date: 2015-09-01 Impact factor: 25.391
Authors: O R Benavente; C S Coffey; R Conwit; R G Hart; L A McClure; L A Pearce; P E Pergola; J M Szychowski Journal: Lancet Date: 2013-05-29 Impact factor: 79.321